Intracerebroventricular (ICV) insulin infusion increases TG secretion.

Slides:

Advertisements

Similar presentations

Philip J. Barter, et al. Circulation 2011;124:

Advertisements

Independent variables (baseline) Loge (HOMA-IR) b P

Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Figure 2 Evidence for the incretin effect and

HPLC tracings of resveratrol (RV) and its major sulfate conjugates M4/M5 in the plasma from three subjects. HPLC tracings of resveratrol (RV) and its major.

Insulin and glucagon secretion: nondiabetic and diabetic subjects.

Brain Insulin Controls Adipose Tissue Lipolysis and Lipogenesis

The ERK phosphorylation inhibitor U0126 did not block the memory-enhancing effects of E2 in intact or GDX males. The ERK phosphorylation inhibitor U0126.

Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.

Brain glucose metabolism lowers plasma triglycerides

Fasting plasma adiponectin concentration in relation to body mass index (BMI) (A), waist circumference (B), acute insulin response (AIR) (C) and insulin.

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Comparison of triglycerides AUC 480’ between IGT+reduced FPIS group, IGT+preserved FPIS group, and IGT+reduced FPIS+reduced FPIS and FPIS restitution with.

Hyperinsulinemic-euglycemic clamps revealed that obese TPL2KO mice have an improved insulin sensitivity compared with obese WT mice. Hyperinsulinemic-euglycemic.

Central nervous system BDNF infusion fails to increase tissue glucose uptake in uncontrolled insulin-deficient diabetes. Central nervous system BDNF infusion.

A–L: Xenin-25 amplifies the effects of GIP on plasma insulin, C-peptide, and glucose levels and ISRs in humans with NGT and IGT but not T2DM. A–L: Xenin-25.

Deletion of neuronal insulin receptor signaling reduces TG secretion, while the targeted knockout of insulin receptors restricted to the periphery increases.

Results for HbA1c (A), severe or BG-confirmed symptomatic hypoglycemia (B), change in body weight (C), daily total insulin dose (D), FPG (E), and nine-point.

A–F: Xenin-25 amplifies the insulin secretory response to GIP in humans with NGT and IGT but not T2DM. A–F: Xenin-25 amplifies the insulin secretory response.

A and B: Plasma levels of IR-GIP and xenin-25 during GGIs

Glucose, insulin, and AGE levels during an OGC before and after RT

Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.

Chronic brain insulin infusion reduces liver TG content independent of changes in body weight and food intake. Chronic brain insulin infusion reduces liver.

Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.

TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin.

Omental FFA production, calculated from the integrated lipolysis over the last 30 min of each insulin infusion period. Omental FFA production, calculated.

Glucose infusion rate required to maintain the hyperglycemic clamp during the experimental period in sedentary and exercised dogs receiving basal or elevated.

Effect of PIs on insulin release by downstream insulin secretogogues.

Effect of the acute administration of benzylamine plus vanadate on oral glucose tolerance test in STZ-induced diabetic rats. Effect of the acute administration.

Arterial plasma glucose level and peripheral GIR in conscious dogs during the basal (−40 to 0 min) and experimental (0–240 min) periods treated with vehicle.

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

Mean ± SEM concentration of insulin in plasma and CSF and glucose in plasma 30 min after the intraperitoneal administration of DET or NPH insulin at different.

Appearance of insulin in plasma and CSF at different times after the administration of subcutaneous DET and GLAR in mice and the effect of chronic DET.

Plasma growth hormone concentrations during a 65-min infusion of acyl ghrelin at 0.3, 0.9, or 1.5 nmol/kg/h, or saline. Plasma growth hormone concentrations.

Relationships between plasma NEFA concentrations and BMI in two cohorts. Relationships between plasma NEFA concentrations and BMI in two cohorts. Black.

A: The correlation between the GIR and FGU, each measured during the last 40 min of the euglycemic insulin clamp. A: The correlation between the GIR and.

Measurement of insulin release from islets evoked by glucose, diazoxide, and high K+. Measurement of insulin release from islets evoked by glucose, diazoxide,

Glucose tolerance in WT and TRPM2-KO mice.

Fig. 1 Examples of experimental stimuli and behavioral performance.

Effects of in vivo AICAR treatment on blood glucose and lactate concentrations. Effects of in vivo AICAR treatment on blood glucose and lactate concentrations.

Insulin sensitivity in athletes and sedentary normal-weight and obese, young, and old individuals. Insulin sensitivity in athletes and sedentary normal-weight.

Mean plasma concentrations of ampicillin/sulbactam in plasma of critically ill patients with AKI undergoing extended dialysis (duration depicted by box.

Total plasma BCAA (A) and C3 and C5 acylcarnitine (AC) (B) concentrations in the basal state and during insulin infusion in obese subjects before and after.

USP2–45 regulates hepatic gluconeogenesis.

Caloric intake in lean and obese Zucker rats in response to systemic infusion of glucose alone (HG-HI protocol) or glucose with insulin (EuG-HI protocol).

Sympathetic denervation decreases VLDL-TG secretion in the fasted state. Sympathetic denervation decreases VLDL-TG secretion in the fasted state. A: Plasma.

Effect of anandamide on blood glucose clearance and insulin sensitivity. Effect of anandamide on blood glucose clearance and insulin sensitivity. A: Intraperitoneal.

Glucose stimulates GLP-1 secretion from the perfused rat intestine by a dose- and absorption-dependent manner. Glucose stimulates GLP-1 secretion from.

Mean (±SE) plasma glucose concentrations before, during, and after infusions of octreotide (with growth hormone) with saline (•), with insulin replacement.

Effect of cold exposure on determinants of glucose tolerance.

Food intake in response to central infusion of glucose (squares) or insulin (triangles) and in response to successive central infusion of insulin, insulin.

Insulin resistance and hepatic steatosis in ASKO mice.

Treatment of ob/ob mice with TTR-ASOs improves insulin sensitivity.

Effects of Rosi treatment on ASKO mice.

Metabolic effects of VSG in GLP-1r KO mice.

Arterial and hepatic sinusoidal plasma insulin levels in conscious dogs during the basal (−40 to 0 min) and experimental (0–240 min) periods treated with.

Loss of Phb2 in β-cells induces development of diabetes over a 3-week period in β-Phb2−/− mice. Loss of Phb2 in β-cells induces development of diabetes.

Pioglitazone administration acutely inhibits insulin secretion and increases insulin clearance in Wistar rats. Pioglitazone administration acutely inhibits.

Chronic rapamycin treatment impairs β-cell mass and insulin clearance in rats. Chronic rapamycin treatment impairs β-cell mass and insulin clearance in.

(A) Oral glucose tolerance test (OGTT) glucose and (C) natural logarithm of insulin responses over time with SEM bars comparing the first tertile to the.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Effect of empagliflozin on efficacy parameters at week 18.

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

A: Pharmacokinetic (plasma insulin concentration) response to administration of an oral insulin formulation (uninterrupted line) and subcutaneous regular.

(A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects. (A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects.

Four–time point diurnal profiles of plasma glucose concentrations (A) and AUCs (B) over quintiles of HbA1c. ○, AUC1; •, AUC2; ▴, AUC2 − AUC1 (differences.

Hepatic triglyceride content (A), hepatic insulin resistance index (B), and hepatic VLDL1-triglyceride production (C) in responders and nonresponders at.

Presentation transcript:

Intracerebroventricular (ICV) insulin infusion increases TG secretion. Intracerebroventricular (ICV) insulin infusion increases TG secretion. A: Protocol. B: Plasma insulin concentration at baseline (−60 min), at the end (180 min) of the intracerebroventricular insulin infusion, and after intravenous (IV) insulin infusion (n ≥ 5/group). C: Plasma TG accumulation in intracerebroventricular or intravenous insulin– and tyloxapol–injected rats (n ≥ 5/group, except intravenous insulin group: n = 4). D: The calculated VLDL secretion rate combining two independent experimental cohorts (n ≥ 11/group, except intravenous insulin group: n = 5). E: Plasma FA profiles as assessed by gas chromatography; depicted are the absolute changes from time point 0–180 min (n ≥ 6/group). All error bars are SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. intracerebroventricular vehicle group; §P < 0.05, §§P < 0.01, §§§P < 0.001 vs. intracerebroventricular insulin group. Thomas Scherer et al. Diabetes 2016;65:1511-1520 ©2016 by American Diabetes Association